Molecular and cellular biology of moderate-dose (1-10 Gy) radiation and potential mechanisms of radiation protection: Report of a workshop at Bethesda, Maryland, December 17-18, 2001

Radiation Research

Volumn 159, Issue 6, 2003, Pages 812-834

  Coleman, C Norman ^a,h   Blakely, William F ^b   Fike, John R ^c   MacVittie, Thomas J ^d   Metting, Noelle F ^e   Mitchell, James B ^a   Moulder, John E ^f   Preston, R Julian ^g   Seed, Thomas M ^b   Stone, Helen B ^a   Tofilon, Philip J ^a   Wong, Rosemary S L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^e U S DEPARTMENT OF ENERGY   (United States)

^f MEDICAL COLLEGE OF WISCONSIN   (United States)

^g U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^h Building 10 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; AMIFOSTINE; AMINOTHIOL; ANDROSTENEDIOL; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIEMETIC AGENT; ANTIOXIDANT; BIOLOGICAL MARKER; CAPTOPRIL; CHELATING AGENT; COPPER ZINC SUPEROXIDE DISMUTASE; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; KERATINOCYTE GROWTH FACTOR; LOSARTAN; MANGANESE SUPEROXIDE DISMUTASE; MESNA; NITROXIDE DERIVATIVE; OLTIPRAZ; PENTOXIFYLLINE; PROSTAGLANDIN INHIBITOR; SELENIUM; STEM CELL FACTOR; TEMPOL; TOCOPHEROL; UNINDEXED DRUG;

CLINICAL RESEARCH; CONFERENCE PAPER; CYTOGENETICS; DOSIMETRY; FIBROSIS; GASTROINTESTINAL DISEASE; GENE EXPRESSION; HEMATOLOGIC DISEASE; HUMAN; KIDNEY INJURY; LUNG INJURY; MEDICAL EDUCATION; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; RADIATION EXPOSURE; RADIATION INJURY; RADIATION PROTECTION; RADIOBIOLOGY; TREATMENT PLANNING; UNITED STATES;

NON-PROGRAMMATIC;

ANIMALS; CHROMOSOME ABERRATIONS; DNA DAMAGE; HUMANS; MUTATION; OXIDATIVE STRESS; RADIATION DOSAGE; RADIATION INJURIES; RADIATION PROTECTION; RADIOMETRY; RADIOTHERAPY; WHOLE-BODY IRRADIATION;

ANIMALIA;

EID: 0038460321     PISSN: 00337587     EISSN: None     Source Type: Journal    
DOI: 10.1667/RR3021     Document Type: Conference Paper

References (179)

1. T. M. Seed, S. A. Fry, R. Neta, J. F. Weiss, D. G. Jarrett and D. Thomassen, Prevention and treatments: Summary statement. Mil. Med. 167, 87-93 (2002).
2. J. E. Moulder, Report on an interagency workshop on the radiobiology of nuclear terrorism. Radiat. Res. 158, 118-124 (2002).
3. J. E. Moulder, Radiobiology of nuclear terrorism: Report on an interagency workshop (Bethesda, MD, December 17-18, 2001). Int. J. Radiat. Oncol. Biol. Phys. 54, 327-328 (2002).
4. ICRU, Quantities and Units in Radiation Protection Dosimetry. Report 51, International Commission on Radiation Units and Measurements, Bethesda, MD, 1993.
5. D. Followill, P. Geis and A. Boyer, Estimates of whole-body dose equivalent produced by beam intensity modulated conformal therapy. Int. J. Radiat. Oncol. Biol. Phys. 38, 667-672 (1997).
6. J. A. Deye and F. C. Young, Neutron production from a 10MV medical linac. Phys. Med. Biol. 22, 90-94 (1977).
7. NCRP, Neutron Contamination From Medical Electron Accelerators. Report 79, National Council on Radiation Protection and Measurements, Bethesda, MD, 1984.
8. E. J. Hall, S. G. Martin, H. Amols and T. K. Hei, Photoneutrons from medical linear accelerators - radiobiological measurements and risk estimates. Int. J. Radiat. Oncol. Biol. Phys. 33, 225-230 (1995).
9. NCRP, Management of Terrorist Events Involving Radioactive Material. Report 138, National Council on Radiation Protection and Measurements, Bethesda, MD, 1993.
10. D. G. Jarrett, Medical Management of Radiological Casualties, 1st ed. Armed Forces Radiobiology Research Institute, Bethesda, MD, 1999.
11. R. C. Ricks, M. E. Berger and F. M. O'Hara, Jr., Eds., The Medical Basis for Radiation Accident Preparedness: The Clinical Care of Victims. Proceedings of the Fourth International Conference REAC/ TS Conference on the Medical Basis of Radiation Accident Preparedness. CRC Press-Parthenon, London, 2001.
12. 21st Century Biodosimetry: Quantifying the Past and Predicting the Future, Vol. 97(1). Nuclear Technology Publishing, Arlington, VA, 2001.
13. 50 for uniform low LET irradiation of man. Br. J. Radiol. 57, 355-369 (1984).
14. G. H. Anno, S. J. Baum, H. R. Withers and R. W. Young, Symptomatology of acute radiation effects in humans after exposure to doses of 0.5-30 Gy. Health Phys. 56, 821-838 (1989).
15. E. J. Hall, Acute effects of total-body irradiation. In Radiobiology for the Radiologist, 5th ed., pp. 124-135. Lippincott Williams & Wilkins, Philadelphia, 2000.
16. T. J. MacVittie, D. Brown and J. F. Weiss, Eds., Advances in the Treatment of Radiation Injuries. Proceedings of the 2nd Consensus Development Conference on the Treatment of Radiation Injuries, pp. 3-14. Putnam, New York, 1996.
17. D. C. Lloyd, A. A. Edwards, J. E. Moquet and Y. C. Guerrero-Carbajal, The role of cytogenetics in early triage of radiation casualties. Appl. Radiat. Isot. 52, 1107-1112 (2000).
18. J. M. Brown and M. S. Kovacs, Visualization of nonreciprocal chromosome exchanges in irradiated human fibroblasts by fluorescence in situ hybridization. Radiat. Res. 136, 71-76 (1993).
19. B. D. Loucas and M. N. Cornforth, Complex chromosome exchanges induced by gamma rays in human lymphocytes: An mFISH study. Radiat. Res. 155, 660-671 (2001).
20. R. M. Anderson, S. J. Marsden, E. G. Wright, M. A. Kadhim, D. T. Goodhead and C. S. Griffin, Complex chromosome aberrations in peripheral blood lymphocytes as a potential biomarker of exposure to high-LET alpha-particles. Int. J. Radiat. Biol. 76, 31-42 (2000).
21. J. B. Mitchell, W. DeGraff, D. Kaufman, M. C. Krishna, A. Samuni, E. Finkelstein, M. S. Ahn, S. M. Hahn, J. Gamson and A. Russo, Inhibition of oxygen-dependent radiation-induced damage by the nitroxide superoxide dismutase mimic, tempol. Arch. Biochem. Biophys. 289, 62-70 (1991).
22. M. E. C. Robbins, W. Zhao, C. S. Davis, S. Toyokuni and S. M. Bonsib, Radiation-induced kidney injury: A role for chronic oxidative stress? MICRON 33, 133-141 (2002).
23. C. R. Yang, C. Wilson-Van Patten, S. M. Planchon, S. M. Wuerzberger-Davis, T. W. Davis, S. Cuthill, S. Miyamoto and D. A. Boothman, Coordinate modulation of Sp1, NF-kappa B, and p53 in confluent human malignant melanoma cells after ionizing radiation. FASEB J. 14, 379-390 (2000).
24. C. Mothersill and C. B. Seymour, Cell-cell contact during gamma irradiation is not required to induce a bystander effect in normal human keratinocytes: Evidence for release during irradiation of a signal controlling survival into the medium. Radiat. Res. 149, 256-262 (1998).
25. K. Kamiya, J. Yasukawa-Barnes, J. M. Mitchen, M. N. Gould and K. H. Clifton, Evidence that carcinogenesis involves an imbalance between epigenetic high-frequency initiation and suppression of promotion. Proc. Natl. Acad. Sci. USA 92, 1332-1336 (1995).
26. S. A. Amundson and A. J. Fornace, Jr., Gene expression profiles for monitoring radiation exposure. Radiat. Prot. Dosim. 97, 11-16 (2001).
27. D. A. Boothman, I. Bouvard and E. N. Hughes, Identification and characterization of X-ray-induced proteins in human cells. Cancer Res. 49, 2871-2878 (1989).
28. M. H. Barcellos-Hoff and A. L. Brooks, Extracellular signaling through the microenvironment: A hypothesis relating carcinogenesis, bystander effects, and genomic instability. Radiat. Res. 156, 618-627 (2001).
29. I. Hayata, R. Kanda, M. Minamihisamatsu, A. Furukawa and M. S. Sasaki, Cytogenetical dose estimation for 3 severely exposed patients in the JCO criticality accident in Tokai-mura. J. Radiat. Res. 42(Suppl), S149-S155 (2001).
30. R. Kanda, I. Hayata and D. C. Lloyd, Easy biodosimetry for high-dose radiation exposures using drug-induced, prematurely condensed chromosomes. Int. J. Radiat. Biol. 75. 441-446 (1999).
31. J. Bayani and J. A. Squire, Advances in the detection of chromosomal aberrations using spectral karyotyping. Clin. Genet. 59, 65-73 (2001).
32. R. T. Johnson and P. N. Rao. Mammalian cell fusion: Induction of premature chromosome condensation in interphase nuclei. Nature 226, 717-722 (1970).
33. C. A. Waldren and R. T. Johnson, Analysis of interphase chromosome damage by means of premature chromosome condensation after X- and ultraviolet-irradiation. Proc. Natl. Acad. Sci. USA 71, 1137-1141 (1974).
34. W. N. Hittelman and P. N. Rao, Premature chromosome condensation. I. Visualization of x-ray-induced chromosome damage in interphase cells. Mutat. Res. 23, 251-258 (1974).
35. M. N. Cornforth and J. S. Bedford, X-ray-induced breakage and rejoining of human interphase chromosomes. Science 222, 1141-1143 (1983).
36. M. N. Cornforth and J. S. Bedford, On the nature of a defect in cells from individuals with ataxia-telangiectasia. Science 227, 1589-1591 (1985).
37. G. E. Pantelias and H. D. Maillie, Direct analysis of radiation-induced chromosome fragments and rings in unstimulated human peripheral blood lymphocytes by means of the premature chromosome condensation technique. Mutat. Res. 149, 67-72 (1985).
38. J. M. Coco-Martin and A. C. Begg, Detection of radiation-induced chromosome aberrations using fluorescence in situ hybridization in drug-induced premature chromosome condensations of tumour cell lines with different radiosensitivities. Int. J. Radiat. Biol. 71, 265-273 (1997).
39. M. Durante, Y. Furusawa and E. Gotoh, A simple method for simultaneous interphase-metaphase chromosome analysis in biodosimetry. Int. J. Radiat. Biol. 74, 457-462 (1998).
40. P. G. Prasanna, N. D. Escalada and W. F. Blakely, Induction of premature chromosome condensation by a phosphatase inhibitor and a protein kinase in unstimulated human peripheral blood lymphocytes: A simple and rapid technique to study chromosome aberrations using specific whole-chromosome DNA hybridization probes for biological dosimetry. Mutat. Res. 466, 131-141 (2000).
41. National Research Council, Committee on the Biological Effects of Ionizing Radiation, Health Effects of Exposure of Low Levels of Ionizing Radiations (BEIR V). National Academy Press, Washington, DC, 1990.
42. United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR), Sources, Effects, and Risks of Ionizing Radiation. United Nations, New York, 1988.
43. United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR), Biological effects at low radiation doses. In Report to the General Assembly, Vol. II: Effects, pp. 73-175. United Nations, New York, 2000.
44. United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR), DNA repair and mutagenesis. In Report to the General Assembly, Vol. II: Effects, pp. 1-72. United Nations, New York, 2000.
45. W. L. Russell and E. M. Kelly, Specific-locus mutation frequencies in mouse stem-cell spermatogonia at very low radiation dose rates. Proc. Natl. Acad. Sci. USA 79, 539-541 (1982).
46. M. H. Barcellos-Hoff, How do tissues respond to damage at the cellular level? The role of cytokines in irradiated tissues. Radiat. Res. 150 (Suppl.), S109-S120 (1998).
47. C. S. Potten and H. K. Grant, The relationship between ionizing radiation-induced apoptosis and stem cells in the small and large intestine. Br. J. Cancer 78, 993-1003 (1998).
48. F. Paris, Z. Fuks, A. Kang, P. Capodieci, G. Juan, D. Ehleiter, A. Haimovitz-Friedman, C. Cordon-Cardo and R. Kolesnick, Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 293, 293-297 (2001).
49. J. Mora, M. Akram and W. L. Gerald, Comparison of normal and tumor cells by laser capture microdissection. Methods Enzymol. 356, 240-247 (2002).
50. C. Shinohara, G. T. Gobbel, K. R. Lamborn, E. Tada and J. R. Fike, Apoptosis in the subependyma of young adult rats after single and fractionated doses of X-rays. Cancer Res. 57, 2694-2702 (1997).
51. M. L. Monje, S. Mizumatsu, J. R. Fike and T. D. Palmer, Irradiation induces neural precursor-cell dysfunction. Nat. Med. 8, 955-962 (2002).
52. S. Mizumatsu, M. L. Monje, D. R. Morhardt, R. Rola, T. D. Palmer and J. R. Fike, Extreme sensitivity of adult neurogenesis to low doses of X-irradiation. Cancer Res., in press.
53. E. Tada, C. Yang, G. T. Gobbel, K. R. Lamborn and J. R. Fike, Long-term impairment of subependymal repopulation following damage by ionizing irradiation. Exp. Neurol. 160, 66-77 (1999).
54. E. Tada, J. M. Parent, D. H. Lowenstein and J. R. Fike, X-irradiation causes a prolonged reduction in cell proliferation in the dentate gyrus of adult rats. Neuroscience 99, 33-41 (2000).
55. P. J. Tofilon and J. R. Fike, The radioresponse of the central nervous system: A dynamic process. Radiat. Res. 153, 357-370 (2000).
56. T. J. Shors, G. Miesegaes, A. Beylin, M. Zhao, T. Rydel and E. Gould, Neurogenesis in the adult is involved in the formation of trace memories. Nature 410, 372-376 (2001).
57. D. D. Roman and P. W. Sperduto, Neuropsychological effects of cranial radiation: Current knowledge and future directions. Int. J. Radiat. Oncol. Biol. Phys. 31, 983-998 (1995).
58. W. Zhao, D. R. Spitz, L. W. Oberley and M. E. Robbins, Redox modulation of the pro-fibrogenic mediator plasminogen activator inhibitor-1 following ionizing radiation. Cancer Res. 61, 5537-5543 (2001).
59. S. A. Amundson, K. T. Do and A. J. Fornace, Jr., Induction of stress genes by low doses of gamma rays. Radiat. Res. 152, 225-231 (1999).
60. S. A. Amundson, M. Bittner, P. Meltzer, J. Trent and A. J. Fornace, Jr., Induction of gene expression as a monitor of exposure to ionizing radiation. Radiat. Res. 156, 657-661 (2000).
61. S. A. Amundson, K. T. Do, S. Shahab, M. Bittner, P. Meltzer, J. Trent and A. J. Fornace, Jr., Identification of potential mRNA biomarkers in peripheral blood lymphocytes for human exposure to ionizing radiation. Radiat. Res. 154, 342-346 (2000).
62. M. B. Grace, C. B. McLeland and W. F. Blakely, Real-time quantitative RT-PCR assay of GADD45 gene expression changes asa as a biomarker for radiation biodosimetry. Int. J. Radiat. Biol. 78, 1011-1021 (2002).
63. W. F. Blakely, P. G. Prasanna, M. B. Grace and A. C. Miller, Radiation exposure assessment using cytological and molecular biomarkers. Radiat. Prot. Dosim. 97, 17-23 (2001).
64. D. A. Boothman, M. Meyers, N. Fukunaga and S. W. Lee, Isolation of x-ray-inducible transcripts from radioresistant human melanoma cells. Proc. Natl. Acad. Sci. USA 90, 7200-7204 (1993).
65. C. R. Yang, S. Yeh, K. Leskov, E. Odegaard, H. L. Hsu, C. Chang, T. J. Kinsella, D. J. Chen and D. A. Boothman, Isolation of Ku70-binding proteins (KUBs). Nucleic Acids Res. 27, 2165-2174 (1999).
66. C. R. Yang, K. Leskov, K. Hosley-Eberlein, T. Criswell, J. J. Pink, T. J. Kinsella and D. A. Boothman, Nuclear clusterin/XIP8, an x-ray-induced Ku70-binding protein that signals cell death. Proc. Natl. Acad. Sci. USA 97, 5907-5912 (2000).
67. J. K. Leach, G. Van Tuyle, P. S. Lin, R. Schmidt-Ullrich and R. B. Mikkelsen, Ionizing radiation-induced, mitochondria-dependent generation of reactive oxygen/nitrogen. Cancer Res. 61, 3894-3901 (2001).
68. R. C. Benyon and J. P. Iredale, Is liver fibrosis reversible? Gut 46, 443-446 (2000).
69. M. Epperly, J. Bray, S. Kraeger, R. Zwacka, J. Engelhardt, E. Travis and J. Greenberger, Prevention of late effects of irradiation lung damage by manganese superoxide dismutase gene therapy. Gene Ther. 5, 196-208 (1998).
70. J. L. Lefaix, S. Delanian, J. J. Leplat, Y. Tricaud, M. Martin, A. Nimrod, F. Baillet and F. Daburon, Successful treatment of radiation-induced fibrosis using Cu/Zn-SOD and Mn-SOD: an experimental study. Int. J. Radiat. Oncol. Biol. Phys. 35, 305-312 (1996).
71. S. Delanian, F. Baillet, J. Huart, J. L. Lefaix, C. Maulard and M. Housset, Successful treatment of radiation-induced fibrosis using liposomal Cu/Zn superoxide dismutase: clinical trial. Radiother. Oncol. 32, 12-20 (1994).
72. C. Mothersill and C. Seymour, Medium from irradiated human epithelial cells but not human fibroblasts reduces the clonogenic survival of unirradiated cells. Int. J. Radiat. Biol. 71, 421-427 (1997).
73. E. I. Azzam, S. M. de Toledo and J. B. Little, Direct evidence for the participation of gap junction-mediated intercellular communication in the transmission of damage signals from alpha-particle irradiated to nonirradiated cells. Proc. Natl. Acad. Sci. USA 98, 473-478 (2001).
74. H. Nagasawa and J. B. Little, Induction of sister chromatid exchanges by extremely low doses of alpha-particles. Cancer Res. 52, 6394-6396 (1992).
75. H. Zhou, G. Randers-Pehrson, C. A. Waldren, D. Vannais, E. J. Hall and T. K. Hei, Induction of a bystander mutagenic effect of alpha particles in mammalian cells. Proc. Natl. Acad. Sci. USA 97, 2099-2104 (2000).
76. K. M. Prise, O. V. Belyakov, M. Folkard and B. D. Michael, Studies of bystander effects in human fibroblasts using a charged particle microbeam. Int. J. Radiat. Biol. 74, 793-798 (1998).
77. S. G. Sawant, G. Randers-Pehrson, C. R. Geard, D. J. Brenner and E. J. Hall, The bystander effect in radiation oncogenesis: I. Transformation in C3H 101/2 cells in vitro can be initiated in the unir-radiated neighbors of irradiated cells. Radiat. Res. 155, 397-401 (2001).
78. S. G. Sawant, G. Randers-Pehrson, N. F. Metting and E. J. Hall, Adaptive response and the bystander effect induced by radiation in C3H 101/2 cells in culture. Radiat. Res. 156, 177-180 (2001).
79. C. B. Seymour and C. Mothersill, Relative contribution of bystander and targeted cell killing to the low-dose region of the radiation dose-response curve. Radiat. Res. 153, 508-511 (2000).
80. I. Emerit, A. Levy, L. Cernjavski, R. Arutyunyan, N. Oganesyan, A. Pogosian, H. Mejlumian, T. Sarkisian, M. Gulkandanian and L. Merklin, Transferable clastogenic activity in plasma from persons exposed as salvage personnel of the Chernobyl reactor. J. Cancer Res. Clin. Oncol. 120, 558-561 (1994).
81. I. Emerit, M. Quastel, J. Goldsmith, L. Merkin, A. Levy, L. Cernjavski, A. Alaoui-Youssefi, A. Pogossian and E. Riklis, Clastogenic factors in the plasma of children exposed at Chernobyl. Mutat. Res. 373, 47-54 (1997).
82. K. O. Goh, Total-body irradiation and human chromosomes. V. Additional evidence of a transferable substance in the plasma of irradiated persons to induce chromosomal breakages. J. Med. 6, 51-60 (1975).
83. J. G. Hollowell, Jr. and L. G. Littlefield, Chromosome damage induced by plasma of x-rayed patients: An indirect effect of x-ray. Proc. Soc. Exp. Biol. Med. 129, 240-244 (1968).
84. G. S. Pant and N. Kamada, Chromosome aberrations in normal leukocytes induced by the plasma of exposed individuals. Hiroshima J. Med. Sci. 26, 149-154 (1977).
85. R. E. Mitchel, J. S. Jackson, R. A. McCann and D. R. Boreham, The adaptive response modifies latency for radiation-induced myeloid leukemia in CBA/H mice. Radiat. Res. 152, 273-279 (1999).
86. G. Olivieri, J. Bodycote and S. Wolff, Adaptive response of human lymphocytes to low concentrations of radioactive thymidine. Science 223, 594-597 (1984).
87. J. L. Redpath, D. Liang, T. H. Taylor, C. Christie and E. Elmore, The shape of the dose-response curve for radiation-induced neoplastic transformation in vitro: Evidence for an adaptive response against neoplastic transformation at low doses of low-LET radiation. Radiat. Res. 156, 700-707 (2001).
88. S. Wolff, The adaptive response in radiobiology: Evolving insights and implications. Environ. Health Perspect. 106 (Suppl. 1), 277-283 (1998).
89. R. S. Yalow, Concerns with low-level ionizing radiation. Mayo Clin. Proc. 69, 436-440 (1994).
90. R. Neta and P. Okunieff, Cytokine-induced radiation protection and sensitization. Semin. Radiat. Oncol. 6, 306-320 (1996).
91. Y. Chen, P. Rubin, J. Williams, E. Hernady, T. Smudzin and P. Okunieff, Circulating IL-6 as a predictor of radiation pneumonitis. Int. J. Radiat. Oncol. Biol. Phys. 49, 641-648 (2001).
92. X. L. Fu, H. Huang, G. Bentel, R. Clough, R. L. Jirtle, F. M. Kong, L. B. Marks and M. S. Anscher, Predicting the risk of symptomatic radiation-induced lung injury using both the physical and biologic parameters V(30) and transforming growth factor beta. Int. J. Radiat. Oncol. Biol. Phys. 50, 899-908 (2001).
93. M. H. Barcellos-Hoff and S. A. Ravani, Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. Cancer Res. 60, 1254-1260 (2000).
94. A. R. Kennedy and J. B. Little, Protease inhibitors suppress radiation-induced malignant transformation in vitro. Nature 276, 825-826 (1978).
95. C. R. Muirhead, Cancer after nuclear incidents. Occup. Environ. Med. 58, 482-487 (2001).
96. D. A. Pierce and D. L. Preston, Radiation-related cancer risks at low doses among atomic bomb survivors. Radiat. Res. 154, 178-186 (2000).
97. B. Ponnaiya, M. N. Cornforth and R. L. Ullrich, Radiation-induced chromosomal instability in BALB/c and C57BL/6 mice: The difference is as clear as black and white. Radiat. Res. 147, 121-125 (1997).
98. R. L. Ullrich, N. D. Bowles, L. C. Satterfield and C. M. Davis, Strain-dependent susceptibility to radiation-induced mammary cancer is a result of differences in epithelial cell sensitivity to transformation. Radiat. Res. 146, 353-355 (1996).
99. M. A. Bender, A. A. Awa, A. L. Brooks, H. J. Evans, P. G. Groer, L. G. Littlefield, C. Pereira, R. J. Preston and B. W. Wachholz, Current status of cytogenetic procedures to detect and quantify previous exposures to radiation. Mutat. Res. 196, 103-159 (1988).
100. A. L. Brooks, M. A. Khan, R. F. Jostes and F. T. Cross, Metaphase chromosome aberrations as markers of radiation exposure and dose. J. Toxicol. Environ. Health 40, 277-288 (1993).
101. P. G. Prasanna, C. J. Kolanko, H. M. Gerstenberg and W. F. Blakely, Premature chromosome condensation assay for biodosimetry: studies with fission-neutrons. Health Phys. 72, 594-600 (1997).
102. A. L. Brooks, Biomarkers of exposure and dose: State of the art. Radiat. Prot. Dosim. 97, 39-46 (2001).
103. A. T. Natarajan, F. Darroudi and A. T. Ramalho, Cytogenetic indicators of radiation exposure. Adv. Biosci. 94, 263-269 (1994).
104. R. E. Goans, E. C. Holloway, M. E. Berger and R. C. Ricks, Early dose assessment following severe radiation accidents. Health Phys. 72, 513-518 (1997).
105. R. E. Goans, E. C. Holloway, M. E. Berger and R. C. Ricks, Early dose assessment in criticality accidents. Health Phys. 81, 446-449 (2001).
106. N. Wald, Alterations of hematological parameters by radiation. In Triage of Irradiated Personnel (G. I. Reeves, Ed.), pp. 81-88. Armed Forces Radiobiology Research Institute, Bethesda, MD, 1996.
107. L. E. Moore, M. L. Warner, A. H. Smith, D. Kalman and M. T. Smith, Use of the fluorescent micronucleus assay to detect the genotoxic effects of radiation and arsenic exposure in exfoliated human epithelial cells. Environ. Mol. Mutagen. 27, 176-184 (1996).
108. A. A. Romanyukha, V. Nagy, O. Sleptchonok, M. F. Desrosiers, J. Jiang and A. Heiss, Individual biodosimetry at the natural radiation background level. Health Phys. 80, 71-73 (2001).
109. F. W. Whicker, G. Shaw, G. Voigt and E. Holm, Radioactive contamination: State of the science and its application to predictive models. Environ. Pollution 100, 133-149 (1999).
110. G. L. Voelz, Assessment and treatment of internal contamination: General principles. In Medical Management of Radiation Accidents, 2nd ed. (I. A. Gusev, A. K. Guskova and F. A. Mettler, Eds.), pp. 319-336. CRC Press, Boca Raton, FL, 2001.
111. G. L. Voelz, Current approaches to the management of internally contaminated persons. In The Medical Basis for Radiation Accident Preparedness (K. F. Hubner and S. A. Fry, Eds.), pp. 311-325. Elsevier/North Holland, New York, 1980.
112. C. R. Culy and C. M. Spencer, Amifostine: An update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome. Drugs 61, 641-684 (2001).
113. N. Russell, E. Bessell, C. Stainer, A. Haynes, E. Das-Gupta and J. Byrne, Allogeneic haemopoietic stem cell transplantation for multiple myeloma or plasma cell leukaemia using fractionated total body radiation and high-dose melphalan conditioning. Acta Oncol. 39, 837-841 (2000).
114. F. A. Mettler and A. K. Guskova, Treatment of acute radiation sickness. In Medical Management of Radiation Accidents, 2nd ed. (I. A. Gusev, A. K. Guskova and F. A. Mettler, Eds.), pp. 53-67. CRC Press, Boca Raton, FL, 2001.
115. W. Nothdurft, L. Kreja and C. Selig, Acceleration of hemopoietic recovery in dogs after extended-field partial-body irradiation by treatment with colony-stimulating factors: rhG-CSF and rhGM-CSF Int. J. Radiat. Oncol. Biol. Phys. 37, 1145-1154 (1997).
116. J. M. Vose and J. O. Armitage, Clinical applications of hematopoietic growth factors. J. Clin. Oncol. 13, 1023-1035 (1995).
117. A. Gava, L. Bertossi, F. Ferrarese, F. Coghetto, G. Marazzato, A. D. Andrulli and P. L. Zorat, Use of filgrastim, granulocyte colony stimulating factor (G-CSF), in radiotherapy to reduce drop-outs because of radiogenic leukopenia. Radiol. Med. (Torino) 95, 232-236 (1998).
118. B. Glisson, R. Komaki, J. S. Lee, D. M. Shin, F. Fossella, W. K. Murphy, J. Kurie, R. Perez-Soler, R. Schea and S. Vadhan-Raj, Integration of filgrastim into chemoradiation for limited small cell lung cancer: A Phase I study. Int. J. Radiat. Oncol. Biol. Phys. 40, 331-336 (1998).
119. K. M. Zsebo, K. A. Smith, C. A. Hartley, M. Greenblatt, K. Cooke, W. Rich and I. K. McNiece, Radioprotection of mice by recombinant rat stem cell factor. Proc. Natl. Acad. Sci. USA 89, 9464-9468 (1992).
120. 60Co gamma-rays. Zhonghua Zhong Liu Za Zhi 23, 21-24 (2001).
121. A. Van der Meeren, M. A. Mouthon, M. H. Gaugler, M. Vandamme and P. Gourmelon, Administration of recombinant human IL11 after supralethal radiation exposure promotes survival in mice: interactive effect with thrombopoietin. Radiat. Res. 157, 642-649 (2002).
122. C. E. Dunbar, M. Takatoku and R. E. Donahue, The impact of ex vivo cytokine stimulation on engraftment of primitive hematopoietic cells in a non-human primate model. Ann. NYAcad. Sci. 938, 236-244; discussion 244-245 (2001).
123. A. Gratwohl, L. John, H. Baldomero, J. Roth, A. Tichelli, C. Nissen, S. D. Lyman and A. Wodnar-Filipowicz, FLT-3 ligand provides hematopoietic protection from total body irradiation in rabbits. Blood 92, 765-769 (1998).
124. F. J. Hérodin, P. Bourin, J. F. Mayol, J. J. Lataillade and M. Drouet, Short-term injection of antiapoptotic cytokine combinations soon after lethal gamma irradiation promotes survival. Blood 101, 2609-2116 (2003).
125. K. J. Grzegorzewski, K. L. Komschlies, S. E. Jacobsen, F. W. Ruscetti, J. R. Keller and R. H. Wiltrout, Mobilization of long-term reconstituting hematopoietic stem cells in mice by recombinant human interleukin 7. J. Exp. Med. 181, 369-374 (1995).
126. E. Bolotin, M. Smogorzewska, S. Smith, M. Widmer and K. Weinberg, Enhancement of thymopoiesis after bone marrow transplant by in vivo interleukin-7. Blood 88, 1887-1894 (1996).
127. W. Dorr, R. Noack, K. Spekl and C. L. Farrell, Modification of oral mucositis by keratinocyte growth factor: single radiation exposure. Int. J. Radiat. Biol. 77, 341-347 (2001).
128. C. L. Farrell, J. V. Bready, K. L. Rex, J. N. Chen, C. R. DiPalma, K. L. Whitcomb, S. Yin, D. C. Hill, B. Wiemann and D. L. Lacey, Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res. 58, 933-939 (1998).
129. C. L. Farrell, K. L. Rex, S. A. Kaufman, C. R. Dipalma, J. N. Chen, S. Scully and D. L. Lacey, Effects of keratinocyte growth factor in the squamous epithelium of the upper aerodigestive tract of normal and irradiated mice. Int. J. Radiat. Biol. 75, 609-620 (1999).
130. M. J. Kelley, M. Pech, H. N. Seuanez, J. S. Rubin, S. J. O'Brien and S. A. Aaronson, Emergence of the keratinocyte growth factor multigene family during the great ape radiation. Proc. Natl. Acad. Sci. USA 89, 9287-9291 (1992).
131. P. Okunieff, M. Li, W. Liu, J. Sun, B. Fenton, L. Zhang and I. Ding, Keratinocyte growth factors radioprotect bowel and bone marrow but not KHT sarcoma. Am. J. Clin. Oncol. 24, 491-495 (2001).
132. E. S. Yi, S. T. Williams, H. Lee, D. M. Malicki, E. M. Chin, S. Yin, J. Tarpley and T. R. Ulich, Keratinocyte growth factor ameliorates radiation- and bleomycin-induced lung injury and mortality. Am. J. Pathol. 149, 1963-1970 (1996).
133. D. M. Brizel, T. H. Wasserman, M. Henke, V. Strnad, V. Rudat, A. Monnier, F. Eschwege, J. Zhang, L. Russell and R. Sauer, Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J. Clin. Oncol. 18, 3339-3345 (2000).
134. T. R. Sweeney, A Survey of Compounds from the Antiradiation Drug Development Program of the U. S. Army Medical Research and Development Command. Walter Reed Army Institute of Research, Washington, DC, 1979.
135. S. M. Hahn, Z. Tochner, C. M. Krishna, J. Glass, L. Wilson, A. Samuni, M. Sprague, D. Venzon, E. Glatstein and J. B. Mitchell, Tempol, a stable free radical, is a novel murine radiation protector. Cancer Res. 52, 1750-1753 (1992).
136. J. B. Mitchell, A. Russo, P. Kuppusamy and M. C. Krishna, Radiation, radicals, and images. Ann. NY Acad. Sci. 899, 28-43 (2000).
137. D. J. Grdina, Y. Kataoka and J. S. Murley, Amifostine: Mechanisms of action underlying cytoprotection and chemoprevention. Drug Metabol. Drug Interact. 16, 237-279 (2000).
138. J. B. Mitchell and M. C. Krishna, Nitroxides as radiation protectors. Mil. Med. 167, 49-50 (2002).
139. D. J. Grdina, J. S. Murley, Y. Kataoka and W. Epperly, Relationships between cytoprotection and mutation prevention by WR-1065. Mil. Med. 167, 51-53 (2002).
140. M. L. Hensley, L. M. Schuchter, C. Lindley, N. J. Meropol, G. I. Cohen, G. Broder, W. J. Gradishar, D. M. Green, R. J. Langdon, Jr. and D. G. Pfister, American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J. Clin. Oncol. 17, 3333-3355 (1999).
141. M. W. Epperly, J. A. Gretton, S. J. DeFilippi, J. S. Greenberger, C. A. Sikora, D. Liggitt and G. Koe, Modulation of radiation-induced cytokine elevation associated with esophagitis and esophageal stricture by manganese superoxide dismutase-plasmid/liposome (SOD2-PL) gene therapy. Radiat. Res. 155, 2-14 (2001).
142. J. S. Murley, Y. Kataoka, D. E. Hallahan, J. C. Roberts and D. J. Grdina, Activation of NFκB and MnSOD gene expression by free radical scavengers in human microvascular endothelial cells. Free Radic. Biol. Med. 30, 1426-1439 (2001).
143. P. Uma Devi, A. Ganasoundari, B. Vrinda, K. K. Srinivasan and M. K. Unnikrishnan, Radiation protection by the ocimum flavonoids orientin and vicenin: Mechanisms of action. Radiat. Res. 154, 455-460 (2000).
144. S. Delanian, S. Balla-Mekias and J. L. Lefaix, Striking regression of chronic radiotherapy damage in a clinical trial of combined pentoxifylline and tocopherol. J. Clin. Oncol. 17, 3283-3290 (1999).
145. V. Srinivasan and J. F. Weiss, Radioprotection by vitamin E: Injectable vitamin E administered alone or with WR-3689 enhances survival of irradiated mice. Int. J. Radiat. Oncol. Biol. Phys. 23, 841-845 (1992).
146. K. S. Kumar, V. Srinivasan, R. Toles, L. Jobe and T. M. Seed, Nutritional approaches to radioprotection: Vitamin E. Mil. Med. 167, 57-59 (2002).
147. T. J. MacVittie and A. M. Farese, Experimental approaches for therapeutic treatment of radiation-induced hematopoietic injury. In Radiation Toxicology: Bone Marrow and Leukaemia (J. H. Hendry and B. I. Lord, Eds.), Vol. 1, pp. 141-193. Taylor & Francis, London, 1995.
148. R. F. Duarte and D. A. Franf, The synergy between stem cell factor (SCF) and granulocyte colony-stimulating factor (G-CSF): Molecular basis and clinical relevance. Leuk. Lymphoma 43, 1179-1187 (2002).
149. C. Isaacs, N. J. Robert, F. A. Bailey, M. W. Schuster, B. Overmoyer, M. Graham, B. Cai, K. J. Beach, J. W. Loewy and J. A. Kaye, Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin. J. Clin. Oncol. 15, 3368-3377 (1997).
150. J. A. Kaye, FDA licensure of NEUMEGA to prevent severe chemotherapy-induced thrombocytopenia. Stem Cells 16 (Suppl. 2), 207-223 (1998).
151. C. H. Reynolds, Clinical efficacy of rhIL-11. Oncology (Huntingt.) 14, 32-40 (2000).
152. J. B. Bussel, R. Mukherjee and A. J. Stone, A pilot study of rhuIL11 treatment of refractory ITP. Am. J. Hematol. 66, 172-177 (2001).
153. J. P. Caen, Z. C. Han, S. Bellucci and M. Alemany, Regulation of megakaryocytopoiesis. Haemostasis 29, 27-40 (1999).
154. G. Wagemaker, K. J. Neelis, S. C. C. Hartong, A. W. Wognum, G. R. Thomas, P. J. Fielder and D. L. Eaton, The efficacy of recombinant TPO in murine and nonhuman primate models for myelosuppression and stem cell transplantation. Stem Cells 16 (Suppl. 2), 127-141 (1998).
155. W. K. Hofmann, O. G. Ottmann and D. Hoelzer, Memorial lecture. Megakaryocytic growth factors: Is there a new approach for management of thrombocytopenia in patients with malignancies? Leukemia 13 (Suppl. 1), S14-S18 (1999).
156. B. Chung, L. Barbara-Burnham, L. Barsky and K. Weinberg, Radiosensitivity of thymic interleukin-7 production and thymopoiesis after bone marrow transplantation. Blood 98, 1601-1606 (2001).
157. T. J. MacVittie and A. M. Farese, Cytokine-based treatment of radiation injury: potential benefits after low-level radiation exposure. Mil. Med. 167, 68-70 (2002).
158. L. B. Harrison, D. Shasha and P. Homel, Prevalence of anemia in cancer patients undergoing radiotherapy: prognostic significance and treatment. Oncology 63 (Suppl. 2), 11-18 (2002).
159. D. F. Moore and S. Vadhan-Raj, Hematopoietic growth factors in bone marrow failure states. Adv. Biosci. 94, 63-74 (1994).
160. N. S. Tchekmedyian, Anemia in cancer patients: Significance, epidemiology, and current therapy. Oncology (Huntingt.) 16, 17-24 (2002).
161. E. Gluckman, H. A. Broxmeyer, A. D. Auerbach, H. S. Friedman, G. W. Douglas, A. Devergie, H. Esperou, D. Thierry, G. Socie and E. A. Boyse, Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. N. Engl. J. Med. 321, 1174-1178 (1989).
162. M. S. Cairo and J. E. Wagner, Placental and/or umbilical cord blood: An alternative source of hematopoietic stem cells for transplantation. Blood 90, 4665-4678 (1997).
163. M. H. Whitnall, T. B. Elliott, R. A. Harding, C. E. Inal, M. R. Landauer, C. L. Wilhelmsen, L. McKinney, V. L. Miner, W. E. Jackson, 3rd and T. M. Seed, Androstenediol stimulates myelopoiesis and enhances resistance to
164. M. H. Whitnall, C. E. Inal, W. E. Jackson, 3rd, V. L. Miner, V. Villa and T. M. Seed, In vivo radioprotection by 5-androstenediol: stimulation of the innate immune system. Radiat. Res. 156, 283-293 (2001).
165. J. M. Sechler, S. A. Hansal, D. I. Morris, H. I. McFarland and A. S. Rosenberg, Antigen presentation determines the fate of the T memory response in vivo after sublethal gamma-irradiation. J. Immunol. 163, 4701-4706 (1999).
166. S. Singhal and J. Mehta, Reimmunization after blood or marrow stem cell transplantation. Bone Marrow Transplant. 23, 637-646 (1999).
167. I. Brook, T. B. Elliott, G. D. Ledney and G. B. Knudson, Management of postirradiation sepsis. Mil. Med. 167, 105-106 (2002).
168. P. J. Gunter-Smith and A. Dubois, Treatment strategies for radiation-induced gastrointestinal injuries. Adv. Biosci. 94, 195-200 (1994).
169. R. M. Housley, C. F. Morris, W. Boyle, B. Ring, R. Biltz, J. E. Tarpley, S. L. Aukerman, P. L. Devine, R. H. Whitehead and G. F. Pierce, Keratinocyte growth factor induces proliferation of hepatocytes and epithelial cells throughout the rat gastrointestinal tract. J. Clin. Invest. 94, 1764-1777 (1994).
170. E. S. Yi, A. S. Shabaik, D. L. Lacey, A. A. Bedoya, S. Yin, R. M. Housley, D. M. Danilenko, W. Benson, A. M. Cohen and T. R. Ulich, Keratinocyte growth factor causes proliferation of urothelium in vivo. J. Urol. 154, 1566-1570 (1995).
171. T. R. Ulich, L. Whitcomb, W. Tang, P. O'Conner Tressel, J. Tarpley, E. S. Yi and D. Lacey, Keratinocyte growth factor ameliorates cyclophosphamide-induced ulcerative hemorrhagic cystitis. Cancer Res. 57, 472-475 (1997).
172. D. M. Danilenko, B. D. Ring, D. Yanagihara, W. Benson, B. Wiemann, C. O. Starnes and G. F. Pierce, Keratinocyte growth factor is an important endogenous mediator of hair follicle growth, development, and differentiation. Normalization of the nu/nu follicular differentiation defect and amelioration of chemotherapy-induced alopecia. Am. J. Pathol. 147, 145-154 (1995).
173. E. P. Cohen, B. L. Fish and J. E. Moulder, Chronic renal failure is a late complication of exposure to radiation in the myeloablative dose range. In Current Radiation Oncology (J. S. Tobias and P. R. M. Thomas, Eds.), pp. 94-109. Oxford University Press, New York, 1998.
174. E. P. Cohen, B. L. Fish and J. E. Moulder, The renin-angiotensin system in experimental radiation nephropathy. J. Lab. Clin. Med. 139, 251-257 (2002).
175. J. E. Moulder, B. L. Fish and E. P. Cohen, Radiation nephropathy is treatable with an angiotensin converting enzyme inhibitor or an angiotensin II type-1 (AT1) receptor antagonist. Radiother. Oncol. 46, 307-315 (1998).
176. A. Molteni, J. E. Moulder, E. F. Cohen, W. F. Ward, B. L. Fish, J. M. Taylor, L. F. Wolfe, L. Brizio-Molteni and P. Veno, Control of radiation-induced pneumopathy and lung fibrosis by angiotensinconverting enzyme inhibitors and an angiotensin II type 1 receptor blocker. Int. J. Radiat. Biol. 76, 523-532 (2000).
177. F. Sanchiz, A. Milla, N. Artola, J. C. Julia, L. M. Moya, A. Pedro and A. Vila, Prevention of radioinduced cystitis by orgotein: A randomized study. Anticancer Res. 16, 2025-2028 (1996).
178. J. E. Moulder, Pharmacological intervention to prevent or ameliorate chronic radiation injuries. Semin. Radiat. Oncol. 13, 73-84 (2003).
179. H. B. Stone, W. H. McBride and C. N. Coleman, Meeting Report. Modifying normal tissue damage postirradiation. Report of a workshop sponsored by the Radiation Research Program, National Cancer Institute, Bethesda, Maryland, September 6-8, 2000. Radiat. Res. 157, 204-223 (2001).